Clinical Edge Journal Scan

EZ-ALBI score predicts liver function in hepatocellular carcinoma


 

Key clinical point: The EZ albumin-bilirubin (ALBI) score was significantly correlated with the original and more complex ALBI score as a biomarker of liver injury.

Major finding: The correlation coefficient of the EZ-ALBI score with the standard ALBI score was 0.965 ( P < 0.001). In multivariate analysis, factors including EZ-ALBI grade 2 and 3 were independently associated with increased mortality.

Study details: The data come from 3,794 patients newly diagnosed with HCC who were prospectively enrolled in the study and later analyzed.

Disclosures: The study was supported by the Taipei Veterans General Hospital. The researchers had no financial conflicts to disclose.

Source: Ho S-Y et al. Hepatol Res. 2021 May 26. doi:10.1111/hepr.13671.

Recommended Reading

High PIGC expression predicts poor liver cancer survival
Federal Practitioner
High serum Angiopoietin 2 identified patients with HCC
Federal Practitioner
Transplant rejection linked to recurrence of HCC
Federal Practitioner
Study eyes lenvatinib combination in unresectable liver cancer
Federal Practitioner
GINS4 oncogene linked to higher-grade liver cancer, worse survival
Federal Practitioner
Hepatis D virus linked to liver cancer in patients with chronic HBV
Federal Practitioner
Spleen stiffness tied to HCC after HCV treatment
Federal Practitioner
PIVKA-II shows promise as HCC biomarker
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC June 2021
Federal Practitioner
Radiofrequency and microwave ablation show similar success for HCC
Federal Practitioner